2025
Renalase, HIV viremia, and all-cause mortality in people with and without HIV
Chang J, So-Armah K, Guo X, Kundu S, Safirstein R, Marconi V, Freiberg M, Brown S, Justice A, Desir G. Renalase, HIV viremia, and all-cause mortality in people with and without HIV. AIDS 2025, 39: 1490-1494. DOI: 10.1097/qad.0000000000004195.Peer-Reviewed Original ResearchPulmonary Infections in People with HIV
Grammatico M, Shenoi S, Lemieux S, Akgün K. Pulmonary Infections in People with HIV. 2025, 793-819. DOI: 10.1007/978-3-031-77335-8_31.Peer-Reviewed Original ResearchThe Longitudinal Impact of Psychosocial Syndemic Variables on Adherence to Antiretroviral Therapy Among People With HIV in Brazil, Thailand, and Zambia: An Analysis by HIV Transmission Groups in HPTN 063.
Rodríguez-Díaz C, Zangeneh S, Chen Y, Guo X, Tsuyuki K, Ransome Y, Friedman R, Srithanaviboonchai K, Roberts S, Mimiaga M, Mayer K, Safren S. The Longitudinal Impact of Psychosocial Syndemic Variables on Adherence to Antiretroviral Therapy Among People With HIV in Brazil, Thailand, and Zambia: An Analysis by HIV Transmission Groups in HPTN 063. AIDS Education And Prevention 2025, 37: 89-106. PMID: 40323670, PMCID: PMC12334064, DOI: 10.1521/aeap.2025.37.2.89.Peer-Reviewed Original ResearchConceptsSyndemic problemsSyndemic scoreART adherenceHIV transmission groupFear of discriminationOne-year longitudinal dataSuboptimal ART adherenceTransmission groupAssociated with lower ART adherenceSyndemic variableLow ART adherenceHIV preventionTransmission categoryLongitudinal dataAntiretroviral therapyAlcohol useStimulant usePolydrug useLongitudinal impactPWHAdherenceHIVZambiaCareScoresTranscriptomic Alterations Induced by Tetrahydrocannabinol in SIV/HIV Infection: A Systematic Review
Valizadeh A, Veenhuis R, Bradley B, Xu K. Transcriptomic Alterations Induced by Tetrahydrocannabinol in SIV/HIV Infection: A Systematic Review. International Journal Of Molecular Sciences 2025, 26: 2598. PMID: 40141240, PMCID: PMC11942185, DOI: 10.3390/ijms26062598.Peer-Reviewed Original ResearchConceptsSimian immunodeficiency virus (SIV)-infected macaquesPrevalence of cannabis useSIV-infected macaquesChronic immune activationHIV-infected human cellsEpithelial cell proliferationModulate immune responsesSystematic reviewSIV/HIV infectionHIV infectionPreclinical evidencePathways related to inflammationImmune activationCannabis useMicro-RNA expressionImmunomodulatory roleImmunomodulatory effectsReduce inflammationImmune responseTetrahydrocannabinolComprehensive searchCell proliferationTranscriptomic alterationsMethodological qualityPWHPotential Clinical and Economic Impacts of Cutbacks in the President's Emergency Plan for AIDS Relief Program in South Africa : A Modeling Analysis.
Gandhi A, Bekker L, Paltiel A, Hyle E, Ciaranello A, Pillay Y, Freedberg K, Neilan A. Potential Clinical and Economic Impacts of Cutbacks in the President's Emergency Plan for AIDS Relief Program in South Africa : A Modeling Analysis. Annals Of Internal Medicine 2025, 178: 457-467. PMID: 39932732, PMCID: PMC11996594, DOI: 10.7326/annals-24-01104.Peer-Reviewed Original ResearchPresident's Emergency PlanPEPFAR fundingHIV diagnosis ratesClinical HIV outcomesHIV care continuumSouth African adultsNational Institutes of HealthCare continuumHIV outcomesHIV programsAIDS ReliefHIV prevalenceInstitutes of HealthPrimary preventionTreatment engagementEmergency planningPEPFARLife yearsPWHAfrican adultsHIV budgetLife expectancyLong-term detrimental effectsDiagnosis rateProgrammatic implicationsHIV, smoking, and the brain: a convergence of neurotoxicities
Orlinick B, Farhadian S. HIV, smoking, and the brain: a convergence of neurotoxicities. AIDS Research And Therapy 2025, 22: 13. PMID: 39915881, PMCID: PMC11804093, DOI: 10.1186/s12981-025-00714-y.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusCholinergic anti-inflammatory pathwayAnti-inflammatory pathwayNeurocognitive impairmentTobacco smokeEffect of human immunodeficiency virusEffects of tobacco smokingNeurotoxic effectsBrain volume changesClinically significant impactIncreased oxidative stressImmunodeficiency virusAlpha7 nicotinic acetylcholine receptorPWHBrain regionsMicroglial activationCognitive functionBrain healthIncreased neuroinflammationNeuronal apoptosisTherapeutic targetAcetylcholine receptorsGeneral populationNeurotoxicitySmoking379. Potential clinical and economic impact of cutbacks in the United States President's Emergency Plan for AIDS Relief Program in South Africa: a modelling analysis
Gandhi A, Bekker L, Paltiel A, Hyle E, Ciaranello A, Pillay Y, Freedberg K, Neilan A. 379. Potential clinical and economic impact of cutbacks in the United States President's Emergency Plan for AIDS Relief Program in South Africa: a modelling analysis. Open Forum Infectious Diseases 2025, 12: ofae631.010. PMCID: PMC11778235, DOI: 10.1093/ofid/ofae631.010.Peer-Reviewed Original ResearchHIV care cascadeHIV-related deathsCost-effectiveness of Preventing AIDS ComplicationsCare cascadeHIV infectionPEPFAR fundingHIV care continuum outcomesCare continuum outcomesHIV epidemic controlLife expectancyNew HIV infectionsGlobal health initiativesModified societal perspectiveLifetime costsSouth African adultsHealth initiativesHIV diagnosisHIV programsHIV statusPrimary preventionAIDS complicationsPWHPEPFARHIV budgetLife yearsResistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years
Margot N, Jogiraju V, Pennetzdorfer N, Naik V, VanderVeen L, Ling J, Singh R, Dvory-Sobol H, Ogbuagu O, Segal-Maurer S, Molina J, Rhee M, Callebaut C. Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years. The Journal Of Infectious Diseases 2025, 231: 1239-1245. PMID: 39873394, DOI: 10.1093/infdis/jiaf050.Peer-Reviewed Original ResearchOptimized background regimenHIV-1HIV-1 RNA <HIV-1 RNA suppressionTreatment-experienced peopleTandem liquid chromatography/mass spectrometryFirst-in-class inhibitorResistant to 2HIV-1 capsidBackground regimenTreatment-experiencedVirological failureLenacapavirRNA suppressionDrug classesDrug measurementsResistance assaysMonotherapyPWHLiquid chromatography/mass spectrometryTreatmentDrugResistance analysisResuppressionYearsDrug interactions in people with HIV treated with antivirals for other viral illnesses
Okoli A, Ogbuagu O. Drug interactions in people with HIV treated with antivirals for other viral illnesses. Expert Opinion On Drug Metabolism & Toxicology 2025, 21: 383-397. PMID: 39836520, PMCID: PMC12169512, DOI: 10.1080/17425255.2025.2455401.Peer-Reviewed Original ResearchDrug-drug interactionsDrug interactionsManagement of drug interactionsTreatment of HIVViral coinfectionAntiviral therapyHepatitis CViral illnessHIV treatmentIncreased riskPrescribing informationEffective treatmentViral infectionHIVAntiviral agentsConference abstractsPWHPatient outcomesARVDrug prescribing informationTreatmentCoinfectionGoogle ScholarDrugMetabolic pathwaysHarmonization of alcohol use data and mortality across a multi‐national HIV cohort collaboration
Ingle S, Trickey A, Lankina A, McGinnis K, Justice A, Cavassini M, Monforte A, van Sighem A, Gill M, Crane H, Obel N, Jarrin I, Wallner E, Guest J, Silverberg M, Vourli G, Wittkop L, Sterling T, Satre D, Burkholder G, Costagliola D, Sterne J. Harmonization of alcohol use data and mortality across a multi‐national HIV cohort collaboration. Alcohol Clinical And Experimental Research 2025, 49: 407-417. PMID: 39779221, PMCID: PMC11828971, DOI: 10.1111/acer.15522.Peer-Reviewed Original ResearchAUDIT-CAlcohol useAlcohol use dataCohort CollaborationAlcohol Use Disorders Identification TestAssociation of alcohol useAntiretroviral Therapy Cohort CollaborationNo alcohol useDisorders Identification TestJ-shaped relationshipEffects of alcohol useStudy of peopleMeasures of alcohol useHIV Cohort StudyHeavy alcohol useMeasure alcohol useAUDIT-C.Estimate associationsStandard drinksAdult PWHWhite ethnicityCohort studyHigher mortalityItem 1PWHIntegrated Stepped Alcohol Treatment With Contingency Management for Unhealthy Alcohol Use Among People With HIV: A Randomized Controlled Trial
Edelman E, Dziura J, Deng Y, DePhilippis D, Ferguson T, Brown S, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. Integrated Stepped Alcohol Treatment With Contingency Management for Unhealthy Alcohol Use Among People With HIV: A Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2025, 98: 72-81. PMID: 39321757, DOI: 10.1097/qai.0000000000003534.Peer-Reviewed Original ResearchUnhealthy alcohol useSelf-reported abstinenceAlcohol useLost to follow-upContingency managementAlcohol use disorderRandomized Controlled TrialsSubstance use treatmentAlcohol abstinenceFollow-upUse disorderControlled TrialsPWHAlcohol treatmentAbstinenceUse treatmentEvidence of abstinenceHIVWeeksMean proportionTreatmentTrialsAlcoholDaysParticipants
2024
Prostate cancer in people with HIV
Sigel K, Yu R, Chiao E, Deshmukh A, Leapman M. Prostate cancer in people with HIV. Current Opinion In Infectious Diseases 2024, 38: 10-17. PMID: 39624951, PMCID: PMC11695140, DOI: 10.1097/qco.0000000000001076.Peer-Reviewed Original ResearchConceptsProstate cancerHIV infectionContext of HIV infectionOutcomes of prostate cancerIncidence of prostate cancerChronic HIV infectionProstate cancer outcomesProstate cancer burdenEarly detectionEarly ART eraApproaches to early detectionOncological outcomesTumor characteristicsAntiretroviral eraTreatment toleranceHIV statusUninfected personsProstateART eraPatient groupCancer burdenApparent incidenceCancer outcomesPWHHIVA qualitative dyad analysis of barriers and facilitators of antiretroviral therapy (ART) adherence among people who inject drugs (PWID) with HIV in Kazakhstan
Neuenschwander P, Altice F, Remien R, Mergenova G, Sarsembayeva L, Rozental E, Gulyayev V, Davis A. A qualitative dyad analysis of barriers and facilitators of antiretroviral therapy (ART) adherence among people who inject drugs (PWID) with HIV in Kazakhstan. AIDS Care 2024, 37: 151-160. PMID: 39404196, PMCID: PMC11682916, DOI: 10.1080/09540121.2024.2414078.Peer-Reviewed Original ResearchAntiretroviral therapy adherenceSocial supportART adherenceFacilitators of ART adherenceBarriers to ART adherenceAntiretroviral therapyART adherence interventionsInjection drug useDyad analysisAdherence interventionsAdherence barriersLack of awarenessHIV epidemicAdherencePWIDDrug useHIVInterpersonal levelRelationship contextDyad membersFacilitationIndividual levelPWHDyadsIntimate partnersAnalysis of drug–drug interactions in patients with HIV and metabolic syndrome
Tuan J, Igiraneza G, Ogbuagu O. Analysis of drug–drug interactions in patients with HIV and metabolic syndrome. Expert Opinion On Drug Metabolism & Toxicology 2024, 20: 953-965. PMID: 39230187, DOI: 10.1080/17425255.2024.2401044.Peer-Reviewed Original ResearchDrug-drug interactionsAntiretroviral therapyMetabolic disordersMetabolic syndromeNanotechnology-based drug delivery platformsPrevalence of metabolic comorbiditiesSelection of antiretroviral therapyLong-acting antiretroviral therapyContemporary antiretroviral therapyEffective antiretroviral therapyPrevalence of metabolic disordersRepertoire of treatment optionsDrug-drug interaction dataTreat metabolic syndromeMetabolic comorbiditiesTreatment optionsDrug delivery platformPrescribing informationAnalysis of drug-drug interactionsHIVInjectable medicationsDrug prescribing informationWeight lossPWHSyndromeEvaluation of mean corpuscular volume among anemic people with HIV in North America following ART initiation
Lang R, Coburn S, Gill M, Justice A, Grossman J, Gebo K, Horberg M, Mayor A, Silverberg M, McGinnis K, Hogan B, Moore R, Althoff K. Evaluation of mean corpuscular volume among anemic people with HIV in North America following ART initiation. AIDS Research And Therapy 2024, 21: 52. PMID: 39113038, PMCID: PMC11304803, DOI: 10.1186/s12981-024-00641-4.Peer-Reviewed Original ResearchConceptsAntiretroviral therapy initiationAntiretroviral therapyNormocytic anemiaMicrocytic anemiaMean corpuscular volumeRisk factorsMacrocytic anemiaAssociated with increased morbidityCausative factors of anemiaProportion of PWHFactors of anemiaAssociated with increasing ageClassification of anemiaIdentified risk factorsAnemic peopleCD4 countHIV factorsNA-ACCORDLow hemoglobinAnemiaPWHEstimate crudeRobust varianceHemoglobin measurementsHIVBrief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV
Coburn S, Pimentel N, Leyden W, Kitahata M, Moore R, Althoff K, Gill M, Lang R, Horberg M, D'Souza G, Hussain S, Dubrow R, Novak R, Rabkin C, Park L, Sterling T, Neugebauer R, Silverberg M, AIDS F. Brief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024, 96: 393-398. PMID: 39720558, PMCID: PMC11665951, DOI: 10.1097/qai.0000000000003436.Peer-Reviewed Original ResearchNon-AIDS-defining cancersAIDS-defining cancersCancer riskAntiretroviral therapyAntiretroviral therapy classNorth American AIDS Cohort CollaborationCompare cancer riskCancer risk differencesLoss to follow-upInfection-related cancersFollow-upMarginal structural modelsIncident cancerIndividual cancer typesAntiretroviral therapy initiationLonger-term follow-upDuration of follow-upCohort CollaborationCohort studyHazard ratioRisk differenceMonths follow-upPP trialINSTI-based ARTPWHCOVID-19 Breakthrough Infection after Vaccination and Substance Use Disorders: A Longitudinal Cohort of People with and without HIV Receiving Care in the United States Veterans Health Administration
Soyer E, McGinnis K, Justice A, Hsieh E, Rodriguez-Barradas M, Williams E, Park L. COVID-19 Breakthrough Infection after Vaccination and Substance Use Disorders: A Longitudinal Cohort of People with and without HIV Receiving Care in the United States Veterans Health Administration. AIDS And Behavior 2024, 28: 3605-3614. PMID: 39046612, PMCID: PMC12284830, DOI: 10.1007/s10461-024-04449-1.Peer-Reviewed Original ResearchHIV statusSubstance use disordersBreakthrough infectionRisk of breakthroughAssociated with increased riskCOVID-19 breakthrough infectionsSARS-CoV-2Association of substance useSARS-CoV-2 infectionHIV treatment adherenceCD4 countHIV progressionSubstance useUnited States Veterans Health AdministrationHazard ratioIncreased riskPWHCD4PWOHHIVUse disorderVaccinated personsCohort of peopleTreatment adherenceLongitudinal cohortHigh rates of deferring antiretroviral treatment for patients with HIV and substance use disorders: Results from a national sample of HIV physicians in Ukraine
Ottesen T, Wickersham J, Lawrence J, Antoniak S, Zezuilin O, Polonsky M, Antonyak S, Rozanova J, Dvoriak S, Pykalo I, Filippovych M, Altice F. High rates of deferring antiretroviral treatment for patients with HIV and substance use disorders: Results from a national sample of HIV physicians in Ukraine. PLOS ONE 2024, 19: e0305086. PMID: 39028735, PMCID: PMC11259278, DOI: 10.1371/journal.pone.0305086.Peer-Reviewed Original ResearchConceptsAntiretroviral therapy prescriptionAntiretroviral therapyCD4 countSubstance use disordersIncreased levels of stigmaNational sampleLevel of stigmaIndependent of risk groupSuboptimal antiretroviral therapyInitiate antiretroviral therapyPopulation of peopleHIV expertsHIV incidenceHIV physiciansHIV treatmentKey populationsTransgender womenAntiretroviral treatmentFeeling thermometerDrinking alcoholSex workersPhysiciansSex partnersPWHRisk groupsVeteran's Health Administration HIV Care Continuum: 2019 vs 2022
Maier M, Beste L, Lowy E, Hauser R, Van Epps P, Yakovchenko V, Rogal S, Chartier M, Ross D. Veteran's Health Administration HIV Care Continuum: 2019 vs 2022. Open Forum Infectious Diseases 2024, 11: ofae382. PMID: 39086463, PMCID: PMC11288371, DOI: 10.1093/ofid/ofae382.Peer-Reviewed Original ResearchHuman immunodeficiency virusHIV care continuumViral suppressionVL resultsViral loadCare continuumFactors associated with viral suppressionTime of HIV diagnosisHuman immunodeficiency virus careRetrospective cohort analysisMultivariate logistic regressionVirologic suppressionImmunodeficiency virusHIV diagnosisVeterans Health AdministrationReceipt of careCohort analysisHealth care institutionsPWHCare qualityVHA careHealth AdministrationCare institutionsCareVHAConsiderations when prescribing opioid agonist therapies for people living with HIV
Tarfa A, Lier A, Shenoi S, Springer S. Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review Of Clinical Pharmacology 2024, 17: 549-564. PMID: 38946101, PMCID: PMC11299801, DOI: 10.1080/17512433.2024.2375448.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDelayed-Action PreparationsDelivery of Health CareDrug InteractionsHealth Services AccessibilityHIV InfectionsHumansMethadoneNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPre-Exposure ProphylaxisUnited StatesConceptsOpioid agonist therapyOpioid use disorderAntiretroviral therapyAgonist therapyDiagnosed OUDOpioid use disorder managementUse disorderTreatment of opioid use disorderExtended-release naltrexonePotential drug interactionsOpioid use disorder treatmentPrescribed opioid agonist therapyLong-acting formulationPre-exposure prophylaxisOUD outcomesImprove HIV preventionIntersection of HIVOpioid antagonistHIV outcomesHIV epidemicOpioidHIVOpioid use disorder servicesPWHHIV prevention
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply